



CIB Results Review 1Q25

Capital Markets: Overview

In aggregate, banks in this note reported operating revenue of \$67bn, 14% ahead of 1Q24. American and European banks reported similar rates of growth, but with notable difference in the revenue mix: the former outperformed in syndication fees and Equities, while European banks grew their FICC revenue faster. Costs also grew, but at a much slower rate; as a result, the aggregate pre-tax profit jumped 18% y/y.

The exceptional volatility that marked the first 100 days of the new US administration boosted volume-related revenues. VIX hovered around 15 when the new administration arrived; by the end of March, it was firmly in the 20+ territory before hitting 66 in early April, the level last seen five years ago. Unsurprisingly, market operators and liquidity providers reported record volumes in April.





Notes: (1) Tricumen product definitions throughout. (2) Revenue is post-writedowns, excludes DVA/equivalent and one-offs. (3) Headcount: Front office full-time equivalent, adjusted for seniority. (4) Pre-tax profit excludes Prop & Principal Investments.



Capital Markets (cont.): Banking


<u>DCM</u> loan syndication volumes were slightly ahead of 1Q24, with strong growth in both Europe and the US; however, APAC volumes dropped almost 30% y/y. Bonds had a great start to the year as strong demand from emerging markets (including China) and international issuers more than offset a dip in high grade and high yield corporate volumes.


Apollo, Carlyle and Ares recently participated in the issuance of Significant Risk Transfer securities which referenced loans to Business Development Companies. This is an innovative approach which could help banks free up capital.

MBS issuance jumped 33% y/y; ABS advanced 4% y/y, but was 30% ahead of 4Q24.

In <u>ECM</u>, IPO volumes, strong in January, declined in February and March as the uncertainty created by the new US administration dampened the volumes. IPO fees jumped to the highest level since 1Q22; but APOs and converts weakened. Regionally, US volumes declined, while Europe and APAC saw strong growth.

<u>M&A/Advisory</u> fees grew 15% y/y, driven by mega-deals; and regionally, by APAC and Europe. The US volumes declined amid a sharp fall in bids for US targets. Private equity-backed dealmaking continues to grow.






Notes: (1) Tricumen product definitions throughout. (2) Revenue is post-writedowns, excludes DVA/equivalent and one-offs. (3) Headcount: Front office full-time equivalent, adjusted for seniority.




Capital Markets (cont.): FICC

Macro revenues surged across all the main areas. <u>FX</u> spot volumes on Cboe and Euronext hit new highs, and the demand for hedging against a decline in US\$ surged. The 2Q25 had a very strong start, driven by the explosion in volatility in April. In <u>Rates</u>, Record volumes were seen in repo, US and European govies. The sell-off in US Treasuries raised fears of the liquidity crunch, with munis seen as a low-risk alternative. <u>Commodities</u> revenue jumped, led by the US majors.

<u>Credit</u> revenue declined slightly; however, ADVs hit records in corporate bonds, US e-trading (high grade and high yield) and European credit. The high hopes of electronification in credit markets have not (yet?) been realised; the rate of growth of primarily-electronic volumes slowed significantly in late 2024 and 1Q25 and main market makers' revenue remains driven by voice.



% change share of peer group operating revenue and pre-tax profit: (1Q25 / 1Q24)



Notes: (1) Tricumen product definitions throughout. (2) Revenue is post-writedowns, excludes DVA/equivalent and one-offs. (3) Headcount: Front office full-time equivalent, adjusted for seniority. (4) Pre-tax profit excludes Prop & Principal Investments.

3/9





Capital Markets (cont.): Equities

A surge in volatility and client flows boosted revenue; several banks in this report set new multi-year records. Revenue from <u>equity derivatives</u> grew the most, led by banks with strong Options and high-margin emerging markets offerings.

<u>Prime services</u> also jumped, supported by higher client balances. Market volatility in March hit equity-focused hedge funds particularly hard; uncorrelated strategies held up well, though.

<u>Cash equity</u> grew across all regions. The market selloff in the US in 1Q25 was driven by institutional and retail investors' fundamental concerns, rather than hedge funds rushing for exit.







Notes: (1) Tricumen product definitions throughout. (2) Revenue is post-writedowns, excludes DVA/equivalent and one-offs. (3) Headcount: Front office full-time equivalent, adjusted for seniority. (4) Pre-tax profit excludes Prop & Principal Investments.



Commercial Banking & Treasury Services

- In <u>Europe</u>, the tightening of credit standards was smaller than generally expected, and was driven almost entirely by banks in Germany (and four smaller Eurozone countries). Demand for corporate loans softened slightly across LME and SME market sectors. In the <u>US</u>, corporate loan demand grew throughout the 1Q25, ending the quarter only slightly below 1Q24.
- A notable increase in payments and trade financing volumes partly offset by margin compression in deposits - seen in 1Q25 may taper off: the trade war could reduce the revenue from payments.





Notes: (1) Tricumen product definitions throughout. (2) Revenue is post-writedowns, excludes DVA/equivalent and one-offs. (3) Headcount: Front office full-time equivalent, adjusted for seniority. (4) In-scope: Large Cap/MNC and Mid-Cap/SMEs.



Revenue dynamics


1Q25/1Q24 (Operating revenue, % change, US\$)

	BAML	BARC	BNPP	Citi	DBK	GS	HSBC	JPM	MS	RBC	SocGen	UBS	WFC
apital Markets	<u> 1</u>	1	2	Σ	<u> 1</u>	Ţ	•	\sim	2	\sim	1	2	Û
Banking	Ŷ	Σ	Σ	Z	Ŷ	1	2	2	2	•	•	Ŷ	∑
DCM Bonds	1	2	2	2	Ţ	Σ	<u>S</u>	<u> </u>	<u>1</u>	•	•	2	Ţ
DCM Loans	1	1	\sim	1	Ţ	\sim	S	1	1	\sim	1	1	
Securitisation	1	2	₽	2	2	1	1	Ţ	1	\sim	1		1
ECM	1	Σ	1	1	2	1	•	Ţ	1	\sim		1	1
M&A / Advis	1	1	2	1	~	1	\sim	2	2	\sim	\sim	Ţ	1
Markets	2	2	Z	2	<u> </u>	2	•	Z	Z	<u> </u>	₽	7	Ŷ
FICC	Z	2	2	Z	2	Ţ	•	2	1	Ţ	Ţ	Z	Z,
FX & Loc Mkts	2	1	2	\simeq	<u> </u>	2	2	4	2	•	1	•	<u> 1</u>
Rates & Fin & Muni	\sim	Z	Φ	\sim	2	1	•	•	1	1	1	Ţ	Ţ
Credit	2	Z	1	\sim	\sim	2	•	<u>1</u>	1	2	1		Ţ
Commodities	1		1	\sim		\sim	\sim		1	1	Ţ.	1	
Equities	2	2	•	Z	<u>1</u>	1	8	1	•	1	S	Z	<u> </u>
EQ Cash	2	Z	•	Z	· · · · · · · · · · · · · · · · · · ·	$\overline{\lambda}$	$\overline{\lambda}$	2	2	2	1	•	Ţ
EQ Der'v & Conv't	1	1	2	1	1	\sim	4	\sim	5	1	<u>S</u>	Ţ	Ţ
Prime Services	Ž,	2	1	Ž,		1	Ž,	Z	1	Ţ	2		2
Prop & PI			4				-	1					
omm Bank / Treasury Services	<u> </u>	1	Σ	Ŷ	Ŷ		<u>S</u>	\sim		•	Ţ		<u> </u>
Comm Bank	1	1	1	<u></u>	₽		₽	<u></u>		2			<u>S</u>
Treasury Services	Ť	2	2	2	Ŷ		2	Ä		•	2		1


Source: Tricumen. Notes: (1) Tricumen product definitions throughout. (2) Arrows show % change in revenue vs peers. Up-/down-arrows: top-/bottom-quartile. (3) Operating revenue is post-writedowns, excludes DVA/equivalent and one-offs. (4) Commercial/Transaction Banking includes Large Cap/MNC and Mid-Cap/SMEs. (5) outliers are excluded.




Pre-tax profit margin (US\$)



FICC Equities



Commercial Banking / Treasury Services




Source: Tricumen. Notes: (1) TRIC product definitions, standard deviation, product Level 1; (2) Operating expenses exclude one-off non-operational items, insurance-related benefits & claims, and credit expense/recovery/NPL provisions. Capital expenditure is included as accrued. Litigation expense is allocated to front-line units. (3) positive values = outperformance; negative values = underperformance, relative to the peer group featured in this report; (4) missing values = N/M; no Tricumen coverage; or the bank is not a significant competitor; (5) outliers are excluded.




Operating Revenue / Front Office FTE (US\$)

Capital Markets Banking BAML BAML 2.0 1.5 WFC BARC WFC BARC 1.5 1.0 1.0 0.5 BNPP **UBS** UBS, BNPP 0.5 0.0 SocGen SocGen RBC √ DBK **RBC** √ DBK • 1Q25 • 1Q25 HSBC HSBC **- - -** Avg **– – –** Avg

FICC Equities



Commercial Banking / Treasury Services



Source: Tricumen. Notes: (1) TRIC product definitions, standard deviation, product Level 1; (2) positive values = outperformance; negative values = underperformance, relative to the peer group featured in this report; (3) missing values = N/M; no Tricumen coverage; or the bank is not a significant competitor; (4) outliers are excluded.



About Tricumen

Tricumen was founded in 2008. It quickly became a strong provider of diversified market intelligence across the capital markets and has since expanded into transaction and corporate banking, asset servicing, and asset and wealth management. Tricumen's data has been used by many of the world's leading investment banks as well as strategy consulting firms, investment managers and 'blue chip' corporations.

Situated near Cambridge in the UK, Tricumen is almost exclusively staffed with senior individuals with an extensive track record of either working for or analysing banks; and boasts what we believe is the largest financial markets-focused research network of its peer group.

Notes & Caveats

Tricumen Limited places no restrictions on reproduction or transmission of data contained in this report, provided that information released is sourced to Tricumen Limited and that it does not prejudice Tricumen Limited's business or compromise the company's ability to analyse the financial markets. Full acknowledgement of Tricumen Limited must be given.

Tricumen Limited has used all reasonable care in writing, editing and presenting the information found in this report. All reasonable effort has been made to ensure the information supplied is accurate and not misleading. For the purposes of cross- market comparison, all numerical data is normalised in accordance to Tricumen Limited's proprietary product classification. Fully-researched dataset may contain margin of error of 10%; for modelled datasets, this margin may be wider.

The information and commentary provided in this report has been compiled for informational purposes only. We recommend that independent advice and enquiries should be sought before acting upon it. Readers should not rely on this information for legal, accounting, investment, or similar purposes. No part of this report constitutes investment advice, any form of recommendation, or a solicitation to buy or sell any instrument or to engage in any trading or investment activity or strategy. Tricumen Limited does not provide investment advice or personal recommendation nor will it be deemed to have done so.

Tricumen Limited makes no representation, guarantee or warranty as to the suitability, accuracy or completeness of the report or the information therein. Tricumen Limited assumes no responsibility for information contained in this report and disclaims all liability arising from negligence or otherwise in respect of such information.

Tricumen Limited is not liable for any damages arising in contract, tort or otherwise from the use of or inability to use this report or any material contained in it, or from any action or decision taken as a result of using the report.

© Tricumen Limited 2025. All rights reserved